Author : Megan Laura Kerr
Publisher :
Page : 496 pages
File Size : 29,22 MB
Release : 2012
Category :
ISBN :
Alzheimer's disease (AD) is characterised by an accumulation of the [beta]-amyloid (A[beta]) in the brain. A[beta]-induced neuronal dysfunction in AD is probably mediated via a direct interaction with components of the neuronal cell membrane. Genetic and molecular evidence suggests that cholesterol and lipoprotein homeostasis influence AD pathogenesis, however the mechanism by which this occurs is unclear. The present study aimed to examine whether cholesterol or lipoprotein factors regulate the binding of A[beta] to neuronal cells. To examine A[beta]-cell binding, an N-terminal fluorescein (Fluo) conjugate of the 42-amino acid isoform of A[beta] (A[beta]1-42; FluoA[beta]1-42) was incubated with SH-SY5Y human neuroblastoma cells, and cell-¬associated fluorescence was measured by confocal microscopy and flow cytometry. FluoA[beta]1-42 bound to cells in an aggregation-dependent manner, and was internalised to late endocytic compartments. The cell binding and uptake of FluoA[beta]1-42 was not mediated by binding sites for either cholera toxin B subunit, or antibodies to the low-density lipoprotein-related protein 1 (LRPl). These data suggested that FluoA[beta]1-42 did not bind to GMl gangliosides or LRPI on the cell surface. However, FluoA[beta]1-42 did colocalise to the binding sites of the LRPI ligand, receptor-associated protein (RAP), on the plasma membrane. Moreover, co¬incubation with RAP enhanced the binding of A[beta] to cells, and A[beta] was immunoprecipitated by an anti-RAP antibody following the incubation of RAP with A[beta] in vitro. By SDS-PAGE, it was also observed that RAP inhibited the oligomerisation of A[beta], and formed an SDS-stable complex with A[beta]. An inhibition of A[beta] aggregation was also noted by atomic force microscopy. Since A[beta] aggregation alters its toxicity, the effect of RAP on A[beta]-induced neurotoxicity was tested. RAP inhibited both the A[beta]-induced increase in intracellular calcium of SH-SY5Y cells, and A[beta]-induced amnesia in chicks. Since the aggregation of A[beta] into SDS-stable low molecular weight oligomers has been closely linked to A[beta] neurotoxicity and AD, the effect of RAP on A[beta] oligomerisation was examined in more detail. RAP inhibited the formation of SDS-stable dimers of A[beta]. The binding and uptake of A[beta] and RAP-A[beta] by SH-SY5Y cells was inhibited by heparin. However, heparin did not inhibit the formation of the RAP-A[beta] complex, suggesting that the binding of A[beta] to cells involves its heparin-binding domains, whereas the binding of A[beta] to RAP does not. Together, these findings suggest that RAP alters A[beta] aggregation, cellular uptake of A[beta], and A[beta]-induced neuronal dysfunction. Therefore, the RAP-A[beta] interaction may be a viable target for the development of AD therapies.